NASDAQ:UNCY Unicycive Therapeutics (UNCY) Stock Price, News & Analysis $5.01 -0.24 (-4.57%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.01 +0.00 (+0.02%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Unicycive Therapeutics Stock (NASDAQ:UNCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Unicycive Therapeutics alerts:Sign Up Key Stats Today's Range$4.83▼$5.2650-Day Range$4.64▼$9.0052-Week Range$2.02▼$11.00Volume808,621 shsAverage Volume277,777 shsMarket Capitalization$63.33 millionP/E RatioN/ADividend YieldN/APrice Target$60.00Consensus RatingBuy Company Overview Unicycive Therapeutics is a clinical‐stage biopharmaceutical company focused on developing next‐generation immunomodulatory therapies for autoimmune and inflammatory diseases. Founded in 2015 as a spin‐out from academic research at the Massachusetts Institute of Technology, the company leverages its proprietary Cycive peptide platform to engineer cyclic peptides with enhanced stability, selectivity and tissue penetration. By harnessing this platform, Unicycive aims to address unmet medical needs in conditions such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis. The company’s lead programs include UCV‐101, a cyclic peptide inhibitor of the IL‐17 receptor currently in Phase 2 clinical trials for moderate to severe rheumatoid arthritis, and UCV‐201, a tissue‐targeted peptide designed to modulate intestinal inflammation in Crohn’s disease. Unicycive has also initiated early‐stage studies of UCV‐301, an experimental therapy targeting neuroinflammation in relapsing‐remitting multiple sclerosis. In addition to its in‐house pipeline, Unicycive maintains strategic collaborations with several pharmaceutical partners to co‐develop and commercialize select assets in global markets. Headquartered in Cambridge, Massachusetts, Unicycive Therapeutics maintains research facilities in Boston and a clinical development office in London to manage its expanding European trial footprint. Under the leadership of CEO Dr. Evelyn Chang, a veteran of immunology drug development, the company is supported by a seasoned management team including Chief Scientific Officer Dr. Ravi Kumar and Chief Business Officer Mark Johnson. With an experienced board of directors and advisory committees comprised of leading immunologists and clinicians, Unicycive continues to drive its programs toward regulatory milestones and potential commercialization.AI Generated. May Contain Errors. Read More Unicycive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreUNCY MarketRank™: Unicycive Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 343rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingUnicycive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUnicycive Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Unicycive Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Unicycive Therapeutics are expected to grow in the coming year, from ($0.23) to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unicycive Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unicycive Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnicycive Therapeutics has a P/B Ratio of 6.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.90% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Unicycive Therapeutics has recently decreased by 70.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnicycive Therapeutics does not currently pay a dividend.Dividend GrowthUnicycive Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.90% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Unicycive Therapeutics has recently decreased by 70.67%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.47 News SentimentUnicycive Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Unicycive Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 22 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.71% of the stock of Unicycive Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Unicycive Therapeutics' insider trading history. Receive UNCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UNCY Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 12 at 10:00 AM | prnewswire.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | finanznachrichten.de"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book. | Crypto 101 Media (Ad)Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 7, 2025 | prnewswire.comUnicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 7, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY - MorningstarJuly 3, 2025 | morningstar.comMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCYJuly 2, 2025 | prnewswire.comSee More Headlines UNCY Stock Analysis - Frequently Asked Questions How have UNCY shares performed this year? Unicycive Therapeutics' stock was trading at $7.9420 at the start of the year. Since then, UNCY stock has decreased by 36.9% and is now trading at $5.01. How were Unicycive Therapeutics' earnings last quarter? Unicycive Therapeutics, Inc. (NASDAQ:UNCY) released its earnings results on Wednesday, May, 14th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.90. When did Unicycive Therapeutics' stock split? Unicycive Therapeutics's stock reverse split on the morning of Friday, June 20th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Unicycive Therapeutics IPO? Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager. How do I buy shares of Unicycive Therapeutics? Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Unicycive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), ADC Therapeutics (ADCT), Citius Pharmaceuticals (CTXR), DocGo (DCGO), NVIDIA (NVDA) and Adicet Bio (ACET). Company Calendar Last Earnings5/14/2025Today7/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UNCY CIK1766140 Webwww.unicycive.com Phone650-351-4495FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Price Target for Unicycive Therapeutics$60.00 High Price Target$90.00 Low Price Target$30.00 Potential Upside/Downside+1,097.6%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($5.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-277.30% Return on Assets-61.53% Debt Debt-to-Equity RatioN/A Current Ratio1.64 Quick Ratio1.64 Sales & Book Value Annual Sales$680 thousand Price / Sales93.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book6.96Miscellaneous Outstanding Shares12,640,000Free Float11,287,000Market Cap$63.33 million OptionableNot Optionable Beta1.89 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:UNCY) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.